According to GuruFocus Insider Data, the recent CFO sales were: Tyson Foods Inc. (TSN, Financial), Alexion Pharmaceuticals Inc. (ALXN, Financial) and Gilead Sciences Inc. (GILD, Financial).
Tyson Foods Inc.: EVP and CFO Dennis Leatherby sold 110,966 shares
On Dec. 2, EVP and CFO Dennis Leatherby sold 110,966 shares at an average price of $50.71. The price of the stock has increased by 3.57%. Tyson Foods Inc. has a market cap of $19.2 billion and its shares were traded at around $52.52. The company has a P/E ratio of 17.73 and P/S ratio of 0.52 with a dividend yield of 0.86%. Over the past 10 years, Tyson Foods Inc. had an annual average earnings growth of 12.80%.
Tyson Foods announced its 2015 third-quarter results with revenues of $10.51 billion and gross profit of $986 million; the net income was $258 million. The 2015 total revenue was $41.37 billion, a 10% increase from the 2014 total revenue. The 2015 gross profit was $3.92 billion, a 46% increase from the 2014 gross profit. The 2015 net income was $1.22 billion.
On Nov. 30, President and CEO Donald Smith (Trades, Portfolio) sold 102,901 shares at an average price of $50. The price of the stock has increased by 5.04%. On Nov. 27, Director Antonio Berlanga, bought 18,500 shares at an average price of 11 cents per share. The price of the stock has increased by 5.04%. On Dec. 9, Director Jim D. Kever sold 5,000 shares at an average price of $52.65. The price of the stock has decreased by 0.25%.
Alexion Pharmaceuticals Inc.: EVP and CFO Vikas Sinha sold 675 shares
On Aug. 4, EVP and CFO Vikas Sinha sold 675 shares at an average price of $196.52 per share. The price of the stock has decreased by 4.3%. Alexion Pharmaceuticals Inc. has a market cap of $42.37 billion and its shares were traded at around $188.06. The company has a P/E ratio of 153.01 and P/S ratio of 15.73. Over the past five years, Alexion Pharmaceuticals Inc. had an annual average earnings growth of 52.30%.
Alexion Pharmaceuticals Inc. announced its 2015 third-quarter results with revenues of $666.64 million and gross profit of $612.58 million. The 2014 total revenue was $2.23 billion, a 44% increase from the 2013 total revenue. The 2014 gross profit was $2.06 billion, a 50% increase from the 2013 gross profit. The 2014 net income was $656.91 million.
On Aug. 7, CEO David Hallal sold 329 shares at an average price of $190.01 per share. The price of the stock has decreased by 1.03%. On Dec. 8, Director Leonard Bell sold 70,000 shares at an average price of $188.2. The price of the stock has decreased by 0.07%. On Dec. 8, EVP, Chief Strat and Port. Off. Saqib Islam sold 950 shares at an average price of $190. The price of the stock has decreased by 1.02%.
Gilead Sciences Inc.: EVP and CFO Robin L Washington sold 6,250 shares
On Nov. 2, EVP and CFO Robin L Washington sold 6,250 shares at an average price of $109.46. The price of the stock has decreased by 8.62%. Gilead Sciences Inc. has a market cap of $144.16 billion and its shares were traded at around $100.03. The company has a P/E ratio of 9.15 and P/S ratio of 4.94 with a dividend yield of 0.86%. Over the past five years, Gilead Sciences Inc. had an annual average earnings growth of 27.20%.
Gilead Sciences announced its 2015 third-quarter results with revenues of $8.30 billion and gross profit of $7.23 billion; the net income was $4.6 billion. The 2014 total revenue was $24.89 billion, a 122% increase from the 2013 total revenue. The 2014 gross profit was $21.10 billion, a 153% increase from the 2013 gross profit. The 2014 net income was $12.10 billion.
On Dec. 1, Chairman and CEO John C Martin sold 150,000 shares at an average price of $105.82. The price of the stock has decreased by 5.47%. On Dec. 7, President and COO John F Milligan sold 100,000 shares at an average price of $103.18. The price of the stock has decreased by 3.05%. On Dec. 1, EVP, Corp and Med Affairs Gregg H Alton sold 12,000 shares at an average price of $106.01. The price of the stock has decreased by 5.64%.
